Compare · NVO vs TVRD
NVO vs TVRD
Side-by-side comparison of Novo Nordisk A/S (NVO) and Tvardi Therapeutics Inc. (TVRD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and TVRD operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $215.46B, about 8875.2x TVRD ($24.3M).
- Over the past year, NVO is down 12.1% and TVRD is down 93.5% - NVO leads by 81.5 points.
- NVO has been more active in the news (9 items in the past 4 weeks vs 4 for TVRD).
- NVO has more recent analyst coverage (25 ratings vs 14 for TVRD).
- Company
- Novo Nordisk A/S
- Tvardi Therapeutics Inc.
- Price
- $48.65+3.65%
- $1.82+2.25%
- Market cap
- $215.46B
- $24.3M
- 1M return
- -2.08%
- -28.35%
- 1Y return
- -12.07%
- -93.53%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2014
- News (4w)
- 9
- 4
- Recent ratings
- 25
- 14
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Berenberg
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
Latest TVRD
- SEC Form 10-Q filed by Tvardi Therapeutics Inc.
- Tvardi Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Tvardi Therapeutics Announces Second Quarter 2026 Results and Provides Business Update
- Tvardi Therapeutics to Host KOL Webinar on the Clinical Potential of TTI-109 in Ulcerative Colitis (UC) and the Evolving Treatment Landscape, on August 19, 2026
- Tvardi Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Tvardi Therapeutics Selects Ulcerative Colitis as Initial Indication for TTI-109
- Tvardi Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- SEC Form 424B5 filed by Tvardi Therapeutics Inc.
- Tvardi Therapeutics upgraded by Piper Sandler with a new price target
- Tvardi Therapeutics upgraded by Raymond James with a new price target